ESMO 2020 | Breast cancer at ESMO 2020: CDK4/6 inhibitors and checkpoint inhibitors

Guy Jerusalem, MD, PhD, University of Liège, Liège, Belgium, summarises the latest breast cancer data presented at ESMO 2020. He outlines the results seen in early stage studies of abemaciclib, a CDK4/6 inhibitor, in an adjuvant setting with endocrine therapy, specifically discussing the potential reduction in side effects in comparison to palbociclib, and the role of abemaciclib in the treatment of highly aggressive tumors. Dr Jerusalem highlights the use of checkpoint inhibitors in triple-negative breast cancer and the need for further data to determine the best checkpoint inhibitor combination drugs. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).